Tobramycin for the treatment of bacterial pneumonia in children

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 565-571

  Bothra, Meenakshi ^a   Lodha, Rakesh ^a   Kabra, Sushil Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antibiotics; Bronchiectasis; Cystic fibrosis; Inhaled antibiotics; Pneumonia; Pseudomonas

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; NETILMICIN; TOBRAMYCIN;

ACINETOBACTER INFECTION; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AUDITORY TOXICITY; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BINDING SITE; BRONCHIECTASIS; BRONCHOSPASM; CHEMICAL STRUCTURE; COUGHING; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FORCED EXPIRATORY VOLUME; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEBULIZER; NEPHROTOXICITY; PATIENT SATISFACTION; PERITONEAL DIALYSIS; PHARYNGITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TINNITUS; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ANTI-INFECTIVE AGENTS; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOBRAMYCIN;

EID: 84857307836     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.656090     Document Type: Review

References (53)

1. Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev 2010;3:CD004874
2. Berman S. Epidemiology of acute respiratory tract infection in children of developing countries. Rev Infect Dis 1990;13(Suppl 60):454-67
3. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8 (Pubitemid 40171240)
4. Sorde R, Pahissa A, Rello J. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect Drug Resist 2011;4:31-41
5. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9
6. Cystic Fibrosis Foundation Patient Registry. Annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda,MD: 2007
7. Hoiby N. Recent advances in the treatment of pseudomonas aeruginosa infection in cystic fibrosis. BMC Med 2011;9:32
8. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46:1105-7 (Pubitemid 34260359)
9. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004;125:62-69S
10. Available from: http://www.drugs.com/ pro/tobramycin.html (accessed on 06.10.2011)
11. TOBI. Tobramycin solution for inhalation [International Prescribing Information]. September 1998
12. Brogden RN, Pinder RM, Sawyer PR, et al. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 1976;12:166-200
13. Warren RL, Baker NR, Johnson J, Stapleton MJ. Selective inhibition of the accumulation of extracellular proteases of Pseudomonas aeruginosa by gentamicin and tobramycin. Antimicrob Agents Chemother 1985;27:468-72 (Pubitemid 15097640)
14. Mugabe C, Halwani M, Azghani AO, et al. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2016-22 (Pubitemid 43807520)
15. Mombelli G, Coppens TL, Thys JP, Klastersky J. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob Agents Chemother 1981;19:72-5 (Pubitemid 11132462)
16. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using pulmosphere technology. J Aerosol Med Pulm Drug Deliv 2011;24:175-82
17. Smith PF, Ballow CH, Booker BM, et al. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;23:1231-44 (Pubitemid 32804116)
18. Blair DC, Fekety FR Jr, Bruce B, et al. Therapy of Pseudomonas aeruginosa infections with tobramycin. Antimicrob Agents Chemother 1975;8:22-9
19. Gounden R, Bamford C, van Zyl-Smit R, et al. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26
20. Chaudhary M, Shrivastava SM, Sehgal R. Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections. Curr Clin Pharmacol 2009;4:62-6
21. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-70
22. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;4:CD004197
23. Diot P, Palmer LB, Smaldone A, et al. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1662-8 (Pubitemid 27505540)
24. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-16
25. Ramsey BW, Pepe MS, Quan JM, et al. Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30 (Pubitemid 29024680)
26. Canton R, Cobos N, de Gracia J et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005;11:690-703 (Pubitemid 41167334)
27. Chuchalin A, Csiszer E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007;9(Suppl 1):21-31 (Pubitemid 46879111)
28. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-80 (Pubitemid 29364062)
29. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44 (Pubitemid 40052376)
30. Brown RB, Kruse JA, Counts GW, et al. Endotracheal Tobramycin Study Group. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother 1990;34:269-72 (Pubitemid 20046879)
31. Le Conte P, Potel G, Clementi E, et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse Med 2000;29:76-8 (Pubitemid 30074538)
32. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44 (Pubitemid 40052376)
33. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5 (Pubitemid 30647187)
34. Rubin BK, Eng M. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21:71-6
35. LoBue PA. Inhaled tobramycin: not just for cystic fibrosis anymore? Chest 2005;127:1098-101
36. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-6 (Pubitemid 46224309)
37. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64
38. Johnson K. Inhaled tobramycin associated with extended survival in cystic fibrosis [abstract 402]. Presented at the Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, Bathesda on 21 October 2010
39. Mulheran M, Hyman-Taylor P, Tan KHV, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006;50:2293-9 (Pubitemid 43993165)
40. Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother 1981;19:859-66 (Pubitemid 11092086)
41. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007;52:866-84
42. Gatell JM, San Miguel JG, Araujo V, et al. Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin. Antimicrob Agents Chemother 1984;26:766-9 (Pubitemid 15211678)
43. Coca A, Martinez A, Soriano E, et al. Tobramycin nephrotoxicity. A prospective clinical study. Postgrad Med J 1979;55:791-6 (Pubitemid 10171590)
44. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9 (Pubitemid 36801771)
45. Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-20 (Pubitemid 39245114)
46. Alothman GA, Alsaadi MM, Ho BL, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122:930-4
47. Dhar R, Anwar GA, Bourke SC, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010;65(6):553
48. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007;37:495-8 (Pubitemid 46855088)
49. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61
50. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63 (Pubitemid 34114228)
51. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011;3:CD001021
52. Prober CG, Walson PD, Jones J; Committee on Infectious Diseases and Committee on Drugs. Technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics 2000;106:E89
53. Parkins MD, Elborn JS. Tobramycin Inhalation Powder: a novel drug delivery system for treating chronic pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011;5:609-22